Risks of Thrombosis and Rehemorrhage During Early Management of Intracranial Hemorrhage in Patients With Mechanical Heart Valves  by Flint, Alexander C. et al.
FIGURE
8
6
4
2
0
Cu
m
ul
at
iv
e 
%
 w
ith
 E
ve
nt
The x-a
cumulat
ruption
anticoag
J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y VO L . 6 6 , N O . 1 5 , 2 0 1 5
ª 2 0 1 5 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C .LettersRisks of Thrombosis and
Rehemorrhage During
Early Management of
Intracranial Hemorrhage
in Patients With
Mechanical Heart ValvesIntracranial hemorrhage in patients with mechanical
heart valves carries a risk of thrombosis and of rehe-
morrhage. Because interruption of anticoagulation
with a mechanical heart valve may lead to thrombotic
events, cardiologist recommendations generally lean
toward minimizing the time off anticoagulation, al-
though valve guidelines do not speciﬁcally address the
duration of anticoagulation interruption (1,2). At the
same time, when anticoagulation is resumed in these
patients, there is a risk of recurrent hemorrhage, and
longer periods of anticoagulation interruption should,
in theory, reduce the risk of rehemorrhage. Because
this scenario is rare, the extent of these 2 competing
risks is poorly understood. Data regarding these risks
come from small single-center retrospective case1 Cumulative Distribution of Thrombotic and Hemorrhage Events
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xis plots 3-day bins of time off anticoagulation; the y-axis displays
ive percentage with thrombotic events during anticoagulation inter-
(solid line) and with intracranial rehemorrhage after resumption of
ulation (dashed line).series, with the largest series to date consisting of
52 patients with intracranial hemorrhage on antico-
agulation for mechanical valves (3).
To help clarify the risks of thrombosis and rehe-
morrhage during the early management of intracra-
nial hemorrhage in patients with mechanical heart
valves, we performed a multicenter retrospective
chart review over a 16-year period (1996 to 2011) in an
integrated health care delivery system (Kaiser Per-
manente Northern California: 18 hospital centers, >3
million patients). Patients were identiﬁed by clinical
database query with conﬁrmation of all cases by
manual chart review. Patients with mechanical valves
with or without concomitant atrial ﬁbrillation were
included, but patients with bioprosthetic valves were
not included.
We identiﬁed 141 mechanical heart valve pati-
ents who had a total of 153 intracranial hemorrhage
events. Forty-four patients died from their initial
intracranial hemorrhage; the remaining 109 hemor-
rhage events had both interruption and resumption of
anticoagulation without hemorrhage expansion dur-
ing anticoagulation interruption. All 109 received
warfarin reversal agents and completed warfarin re-
versal. Operative neurosurgical intervention for the
hemorrhage event was performed in 32 of 109 (29.4%).
Ninety-eight mechanical heart valves (63.8%) were
1 device type (St. Jude Medical, St. Paul, Minnesota).
Thirty-nine (27.7%) mechanical valves were in the
mitral position, 78 (55.3%) were in the aortic position,
21 (14.9%) were in bothmitral and aortic positions, and
3 (2.1%) were in another position.
Thrombotic events occurred in 7 of 109 patients
during anticoagulation interruption (6.4%; 95% CI:
2.6% to 12.8%), including 5 ischemic strokes, 1 epi-
sode of valve thrombosis, and 1 fatal cardiac arrest of
unknown etiology. Thrombotic events occurred in 5
of 52 patients (9.6%) with mechanical valves in the
mitral position (with or without another mechanical
valve), compared to 2 thrombotic events in 57 pa-
tients without a mitral mechanical valve (3.5%), but
this difference was not signiﬁcant (p ¼ 0.26). The type
of warfarin reversal agent used was not predictive of
the risk of thrombotic events.
Rehemorrhage within 2 weeks of anticoagulation
resumption occurred in 4 of 109 patients (3.7%; 95%
CI: 1.0% to 9.3%). All rehemorrhage events occurred
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1739in patients with subdural hematomas (4 of 48 pa-
tients; 8.3%) and consisted of signiﬁcant increase in
subdural hemorrhage with clinical deterioration; no
rehemorrhages occurred in other types of intracranial
hemorrhage (0 of 61 patients; 0%) (p ¼ 0.04). No
rehemorrhages occurred in the 32 patients who had
neurosurgical intervention for their initial hemor-
rhage, compared to 4 recurrent hemorrhages in the 77
patients without neurosurgical intervention, but this
difference was not signiﬁcant (p ¼ 0.32).
All rehemorrhage events occurred during anti-
coagulation resumption after #7 days of antico-
agulation interruption, while less than one-half of the
thrombotic events occurred during an anticoagulation
interruption of #7 days (Figure 1).
Both thrombotic and rehemorrhage events are
relatively uncommon when anticoagulation is inter-
rupted in mechanical heart valve patients with intra-
cranial hemorrhage. While clinical decisions regarding
anticoagulation interruption must be tailored to
an individual patient’s clinical situation, a general
strategy of interrupting anticoagulation for 7 to 10
days may minimize the risk of both thrombotic and
rehemorrhage events. Mechanical heart valve patients
with subdural hematoma may be a group with a higher
risk of recurrent hemorrhage.*Alexander C. Flint, MD, PhD
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Intercalated Discs in
Friedreich CardiomyopathyFriedreich ataxia (FA) is best known for its neuro-
logical phenotype, but the most common cause of
death is heart disease (1). The pathogenesis of FA
cardiomyopathy includes failure to clear iron from
myocytes, chronic inﬂammation, ﬁber necrosis, and
scarring (2). On cross section, heart ﬁbers are
signiﬁcantly enlarged and excessively lobulated (2).
In the longitudinal dimension, the pathogenesis also
involves modiﬁcations of intercalated discs (ICDs),
the plasma membrane specializations that connect
heart ﬁbers end-to-end. Many proteins participate
in the assembly of fascia adherens junctions, des-
mosomes, and gap junctions (GJs) within or near
ICDs (3).
Parafﬁn-embedded heart sections of 15 FA patients
with conﬁrmed homozygous guanine-adenine-
adenine trinucleotide repeat expansions (13 au-
topsies, 1 biopsy specimen, 1 explant) and 12 controls
(all autopsies) were stained with antibodies to N-
cadherin (Figures 1A and 1B), a-actinin, vinculin, and
desmoplakin to visualize fascia adherens junctions
and desmosomes and ZO-1 and connexin 43 to reveal
GJs. N-cadherin reaction product was used to mea-
sure distances between ICDs (Figure 1B, inset) in
sections of the left ventricular wall, right ventricular
wall, and ventricular septum (VS). Strips of ﬁxed VS
were processed for ultrastructural visualization of
ICDs (Figures 1C and 1D).
In FA, all ICDs revealed by immunohistochemistry
(Figure 1A), toluidine blue staining (Figure 1C, inset),
or electron microscopy (Figure 1C) were disorganized,
discontinuous, fragmented, and hyperconvoluted.
N-cadherin reaction product showed an overall
paucity of ICDs (Figure 1A). Connexin 43 reaction
product revealed disorganization of ICDs as well
as lateralization to plasma membranes (not illus-
trated). Inter-ICD distances were signiﬁcantly and
uniformly greater across all heart sections in FA
(76  11 mm) than in controls (54  10 mm; p <0.001,
main effect of FA in analysis of variance), but did not
correlate with age of onset or death, disease duration,
or guanine-adenine-adenine trinucleotide repeat
expansion. Distances between Z discs remained
normal (Figures 1C and 1D).
The underlying mutation in FA causes frataxin
deﬁciency, which may adversely affect ICDs and GJs
before the onset of heart disease and perhaps prena-
tally. The critical step in the faulty assembly and
